Structure Therapeutics' (GPCR) 'Aleniglipron is Well Positioned' - Citizens
Tweet Send to a Friend
Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $87.00 price target on Structure Therapeutics (NASDAQ: GPCR).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
